Autumn 2025
Preview: CROs & CDMOs
CDMOs and CROs are under great pressure to integrate new trial designs and drug formats – including ATMPs, ADCs, condensate blockers, RNA drugs and formulations as well as automated preclinical testing procedures – into their service portfolio, while at the same time facing a global shortage of qualified personnel. In addition to classic antibody and conjugate drugs and various RNA drugs and vaccines, and increasingly to produce cell and gene therapeutics, the first in vivo CRISPR treatments or synthetic peptide hormone combinations are entering the market.
Topics to be covered in this special feature:
- AI-guided cell line selection
- Process development & upscaling & monitoring
- Single-use equipment
- Cell culture and media development
- Glycoengineering
- Conjugation, formulation, fill & finish
- Continuous processing, DSP
- Ex vivo genetic engineering
- NK/MAIT/TCR engineering
- IgG-like bispecifics
- Vector technology
- Plasmid engineering
- Modular UPS and DSP
- Antibody engineering, purification, polishing
Interested in advertising with us? We’re happy to advise you!
Christian Böhm
+49-30-264921-49
c.boehm@biocom
Oliver Schnell
+49-30-264921-45
o.schnell@biocom.de
Andreas Macht
+49-30-264921-54
a.macht@biocom.de
